Navigation Links
Avanir Pharmaceuticals to Participate in Two Conferences in December
Date:11/26/2013

ALISO VIEJO, Calif., Nov. 26, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that company management will present an overview of the company at the following conferences in December.

  • Deutsche Bank 2013 BioFEST
    • Presentation date: Tuesday December 3, 2013
    • Presentation time: 8:25 a.m. E.T.
  • 25th Annual Piper Jaffray Health Care Conference
    • Presentation date: Wednesday December 4, 2013
    • Presentation time: 8:30 a.m. E.T.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

A live webcast and 30-day archive of these presentations will be available at http://ir.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® is a trademark or registered trademark of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Avanir Investor & Media Contact
Ian Clements, PhD
ir@avanir.com 
+1 (949) 389-670
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
2. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
3. AVANIR Pharmaceuticals To participate in two conferences in March
4. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
8. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)...  Steep Hill, the industry leader in cannabis testing ... open a full service medical cannabis quality assurance laboratory ... advanced scientific tools and methodology to the state, for ... currently the only laboratory licensed by the New Mexico ... in order to meet the recently adopted regulatory requirements ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2
... Nanotechnology will significantly change virtually every facet of ... opportunity to shape these changes and to ensure that ... and controlled. A new report by former EPA official ... for the next presidential administration and describes the immediate ...
... Calif., July 23 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ... For the second quarter ended June 30, 2008, ... $0.18 per share, compared to a,net loss of $5.2 ... in 2007.,As of June 30, 2008, the company had ...
... to Present Plans for Regaining Compliance - - NASDAQ ... ... Meets All Other NASDAQ Capital Market Initial Listing ... Rule -, TUSTIN, Calif., July 23 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ...
Cached Biology Technology:Nanotech: A regulatory blueprint for the next administration 2Sangamo BioSciences Reports Second Quarter 2008 Financial Results 2Sangamo BioSciences Reports Second Quarter 2008 Financial Results 3Sangamo BioSciences Reports Second Quarter 2008 Financial Results 4Sangamo BioSciences Reports Second Quarter 2008 Financial Results 5Sangamo BioSciences Reports Second Quarter 2008 Financial Results 6Sangamo BioSciences Reports Second Quarter 2008 Financial Results 7Sangamo BioSciences Reports Second Quarter 2008 Financial Results 8Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 2Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 3Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule 4
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)... MELBOURNE, Fla. , Jan. 13, 2015  Today, ... wearable technology, launched its crowdfunding campaign on Fundable, ... accelerate the build of production capacity to meet ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... National Osteoporosis Foundation, osteoporosis affects more than 2 million ... more have osteopeniaclinically significant low bone density that is ... the University of Missouri-Columbia has found that men engaging ... incidence of osteopeniaa condition resulting in two times the ...
... at the University of Illinois published a discovery that challenged ... which was based on an analysis of ribosomal RNA, ... opened up a new field of study, and established ... To mark the anniversary of this discovery, the university is ...
... of human bones is vastly different than previously believed ... debilitating bone disorders are treated. Researchers from the ... and the BAM Federal Institute of Materials Research and ... stiffness of bone is predominantly due to the presence ...
Cached Biology News:Study shows some athletic men may risk low bone density 2Symposium marks 30th anniversary of discovery of third domain of life 2Symposium marks 30th anniversary of discovery of third domain of life 3Symposium marks 30th anniversary of discovery of third domain of life 4New research on structure of bones raises questions for treatment of osteoporosis 2
... The Fujifilm Life Science FLA-5100 imaging system ... as large as 40 x 46cm at ... microns. This system is especially suitable for ... general array analysis for genomics., Fuji s ...
... and Non-ionic Detergent Removal , ... selective, virtually no cross-reactivity with other proteins ... pellet , Economical new surface technology, ... can often interfere with protein analysis. SurfactAway ...
Physical Form: saline suspension with ethanol Particle Dim: mean particle size 50 μm Matrix: HyperD F. Useful for the removal of detergents from protein samples....
... The Caliper Sciclone ALH 3000 workstation ... diagnostic applications, from Genomic and Proteomic Sample ... Assays. The modular design of the ... options and accessories to perfectly meet the ...
Biology Products: